NCT03927274 is a EARLY_PHASE1 clinical trial of Topotecan in Glioma of Brain, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

Who is sponsoring NCT03927274?

NCT03927274 is sponsored by H. Lee Moffitt Cancer Center and Research Institute.

What drugs are being tested in NCT03927274?

Interventions in NCT03927274: Topotecan.

What condition does NCT03927274 study?

NCT03927274 studies Glioma of Brain.

Is NCT03927274 still recruiting?

NCT03927274 is currently terminated. Last updated 25 May 2023.

Last reviewed 2023-05-25 · How we verify

NCT03927274

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma

Terminated EARLY_PHASE1 Last updated 25 May 2023

What this trial tests

EARLY_PHASE1 trial testing Topotecan in Glioma of Brain in 3 participants. Terminated before completion.

Timeline

20 June 2019

Primary endpoint
24 May 2023

24 May 2023

Quick facts

Lead sponsor	H. Lee Moffitt Cancer Center and Research Institute
Phase	EARLY_PHASE1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	20 June 2019
Primary completion	24 May 2023
Estimated completion	24 May 2023
Sites	1 location across United States

Drugs / interventions tested

Topotecan (topotecan) — full drug profile →

Conditions studied

Glioma of Brain — all drugs for Glioma of Brain →

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Who can join

18 and older, any sex, with Glioma of Brain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine if treatment with Topotecan by an alternative method, delivering topotecan directly into brain tumors, is safe and well tolerated.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Convection-enhanced drug delivery for glioblastoma: a review.
D'Amico RS, Aghi MK, Vogelbaum MA, Bruce JN. · · 2021 · cited 116× · PMID 33611708 · DOI 10.1007/s11060-020-03408-9
Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors.
Griffith JI, Rathi S, Zhang W, Zhang W, et al · · 2020 · cited 47× · PMID 33322488 · DOI 10.3390/pharmaceutics12121205
Breaching the Blood-Brain Tumor Barrier for Tumor Therapy.
Marcucci F, Corti A, Ferreri AJM. · · 2021 · cited 30× · PMID 34063335 · DOI 10.3390/cancers13102391
Research progress of anti-glioma chemotherapeutic drugs (Review).
Zhou YS, Wang W, Chen N, Wang LC, et al · · 2022 · cited 23× · PMID 35362540 · DOI 10.3892/or.2022.8312
Convection-enhanced delivery for high-grade glioma.
Kang JH, Desjardins A. · · 2022 · cited 21× · PMID 35096401 · DOI 10.1093/nop/npab065
Adjuvant convection-enhanced delivery for the treatment of brain tumors.
Kreatsoulas D, Damante M, Cua S, Lonser RR. · · 2024 · cited 19× · PMID 38261143 · DOI 10.1007/s11060-023-04552-8
Convection Enhanced Delivery in the Setting of High-Grade Gliomas.
Nwagwu CD, Immidisetti AV, Jiang MY, Adeagbo O, et al · · 2021 · cited 15× · PMID 33921157 · DOI 10.3390/pharmaceutics13040561
Therapeutic manipulation and bypass of the blood-brain barrier: powerful tools in glioma treatment.
Giantini-Larsen AM, Pandey A, Garton ALA, Rampichini M, et al · · 2025 · cited 8× · PMID 39877748 · DOI 10.1093/noajnl/vdae201

Verify or expand the search:

Other trials of Topotecan

Trials testing the same drug.

NCT07437963 — Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatmen · Phase 1, PHASE2 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07321912 — Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma · Phase 2 · not yet recruiting
NCT06425419 — The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy · Phase 1 · not yet recruiting

Other recruiting trials for Glioma of Brain

Currently open trials in the same condition.

NCT03935685 — Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ · Phase 2 · active not recruiting
NCT03739372 — Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade · NA · active not recruiting
NCT03534050 — Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy · Phase 2, PHASE3 · recruiting
NCT03849430 — Longitudinal Analysis of the Health-related Quality of Life in Glioma Patients · recruiting

Other H. Lee Moffitt Cancer Center and Research Institute trials

Trials by the same sponsor.

NCT05041335 — Wet Heparinized Suction for Abdominal Cancer · NA · not yet recruiting
NCT07222995 — Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs · NA · recruiting
NCT06047977 — Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors · Phase 1 · recruiting
NCT06121180 — Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma · Phase 2 · recruiting
NCT06193486 — Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03927274 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by H. Lee Moffitt Cancer Center and Research Institute
Last refreshed: 25 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03927274.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing